Physician profile
Mark Liebreich
NPI 1669418745
$3,007.94
in general payments reported to CMS, 2019-2025
28 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $211 · 2021: $254 · 2022: $230 · 2023: $679 · 2024: $705 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $528.33 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $359.79 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $248.18 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $220.71 | 2021-2025 | |
| Amgen INC. | $204.90 | 2019-2025 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.03 | 2019-2024 | Xifaxan |
| Pfizer INC. | $177.81 | 2020-2025 | |
| Exact Sciences Corporation | $137.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $133.47 | 2019-2025 | Shingrix, Arexvy |
| Shield Therapeutics INC | $109.51 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $90.54 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $72.32 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $68.17 | 2019-2021 | |
| Esperion Therapeutics, INC. | $63.60 | 2023-2024 | Nexletol |
| Inspire Medical Systems, INC. | $61.02 | 2023-2025 | Inspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.23 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $35.48 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $33.94 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $27.84 | 2019 | |
| Sanofi Pasteur INC. | $24.89 | 2022 | |
| Allergan, INC. | $23.69 | 2020 | |
| Eisai INC. | $23.00 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.61 | 2021 | |
| Axsome Therapeutics, INC. | $22.12 | 2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $21.82 | 2024 | Horizant |
| Abbott Laboratories | $21.44 | 2025 | Proclaim |
| Seqirus USA INC | $17.73 | 2025 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $15.18 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Liebreich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.